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Purpose: Anti-angiogenic therapies are among the most commonly used drugs in renal cell carcinoma. Tumor
vascularity, defined by microvessel area, may be associated with response to these drugs. Clinical studies suggest
that metastatic sites are more responsive than primary tumors. Our purpose was to characterize microvessel area
(MVA) in matched primary and metastatic samples and in samples of different histologies.
Methods: We employed a method of automated, quantitative analysis of in situ tumor components to identify the
area of CD-34 staining endothelial cells within renal cell carcinoma tumors. MVA was assessed in corresponding
primary and metastatic samples from 34 patients, as well as in 334 primary nephrectomy specimens with variable
histologies.
Results: MVA measurements from different parts of the same tumor correlated well (R = 0.75), indicating that MVA
was fairly uniform within a tumor. While MVA was slightly higher in primary tumors than corresponding metastatic
sites, the difference was not statistically significant (P = 0.1). MVA in paired primary and metastatic samples
correlated moderately well (R = 0.36). MVA was higher in clear cell than papillary histology and oncocytomas
(P < 0.0001 and P = 0.018, respectively).
Conclusions: Lack of significant differences MVA in matched primary and metastatic samples suggests that both
types of tumors should respond to anti-angiogenic drugs. This should be confirmed on additional cohorts. Given
the small cohort, future predictive biomarker studies entailing MVA measurements should include specimens from
both sites. Clear cell carcinomas are more vascular than other histologic subtypes, which may explain the higher
response rates to anti-angiogenic therapies in clear cell tumors.
Keywords: Renal cell carcinoma, Microvessel area, AngiogenesisBackground
Renal cell carcinoma (RCC) is fairly common, with an
estimated incidence of 64,000 in the United States in 2012
[1]. Clear cell RCC (ccRCC) is the most prevalent subtype,
reflecting roughly 80% of RCC tumors [2]. RCC tumors
tend to be highly vascular [3]. Studies of tumor neovascula-
ture have revealed silencing of the tumor suppressor von
Hippel-Lindau (VHL) gene or loss of chromosome 3p,
causing activation of hypoxia-inducible transcription factor,
and further production of proangiogenic growth factors,
such as vascular endothelial growth factor (VEGF) [4,5].* Correspondence: Harriet.Kluger@Yale.edu
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reproduction in any medium, provided the orAngiogenesis is critical for sustaining neoplastic growth
and hematogenous dissemination [6,7]. In the past decade,
anti-angiogenic therapies have been shown to be beneficial
in the treatment of advanced metastatic RCC, including
the VEGF targeting drug, bevacizumab, given in conjunc-
tion with interferon, and the VEGF-R2 targeting drugs sor-
afenib, sunitinib, pazopanib and axitinib [8-12]. At present,
no predictive biomarkers are available for selection of
patients for these drugs. Seeing that they target angioge-
nesis, tumor vascularity may be associated with response
to therapy. Our purpose was to determine patterns of
tumor vascularity in historical samples and to compare
vessel density in primary and metastatic RCC tumors.
Response of primary tumors to angiogenesis targeting
agents is variable, however highly sensitive cases (complete
responses) are relatively uncommon. Several groups have. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pre-nephrectomy anti-angiogenic therapy in metastatic
RCC patients [13-16]. However, a recent retrospective
review showed less decrease in primary tumor diameter in
metastatic RCC patients than in metastatic sites [17]. It is
unclear whether there are differences in vessel density in
primary and metastatic RCC tumors, and whether this may
be the cause of possible discordant response in primary and
metastatic sites.
The association between tumor vascularity and response
to VEGF and VEGF receptor targeting drugs remains
unclear. In a small pilot study, vascular permeability mea-
sured radiographically was significantly lower after sorafe-
nib treatment, and this correlated well with time to
progression (P = 0.01). Elevated baseline tumor vascular
permeability correlated with improved progression free
survival (P = 0.003), but not with radiographic decrease in
tumor size. This study included 17 patients and definitive
conclusions cannot be drawn [18]. A similar situation has
been seen with treatment with sunitinib, where dramatic
decreases in vascularity have been seen with little change
in tumor size, and new response criteria based on vascular
permeability are being studied [19].
Limited prior publications have evaluated tumor vascu-
larity in RCC specimens and the association with VHL mu-
tational status and prognosis. VHL mutation, particularly
loss of function mutation, has been shown to be an inde-
pendent prognostic factor in ccRCC. Contradictory results
have been published on the role of microvessel density
(MVD) and VHL mutational status. One small study of 40
cases showed higher levels of MVD in tumors with VHL
mutations, while other studies show no significant correl-
ation between mutational status and MVD [20-23]. Rioux-
Leclercq et al. used standard immunohistochemical staining
for tumor vessels and showed that high tumor vessel
density is associated with poor outcome, while Imao et al.
used similar methods on a small cohort of specimens and
showed the inverse association [24,25]. Conversely,
MacLennan et al. found that while there was no association
between microvessel density and prognosis in ccRCC,
microvessel densities were higher in clear cell and chromo-
phobe histologies [6]. Two additional groups characterized
associations between vessel density and pathological fea-
tures and found an association between high microvessel
area (MVA) and high stage and grade [26,27]. Microvessel
area is defined by an automated quantitative method as the
total area of microvessel in a given sample area. Microvessel
density is defined as countable vessels in a sample area, as
defined by Mlynek et. al [28]. A study by Sullivan et. al in
breast cancer showed high correlation between MVA and
MVD [29]. Yildiz et al. reported an inverse relationship
between microvessel density and microvessel invasion and
metastasis [30]. A major limitation of all of these studies is
use of non-quantitative immunohistochemistry and smallpatient cohorts of less than 70 cases, contributing to
conflicting results. Mertz et al. therefore conducted a
more comprehensive study employing an automated,
quantitative method to assess vessel density applied to a
large cohort of 284 clear cell RCC tumors, and found that
MVA was associated with improved survival [3]. Our
group subsequently validated this finding in a cohort of
over 300 nephrectomy specimens using the same auto-
mated method, and found that high MVA was associated
with improved 10 year disease specific survival (HR = 0.87,
P = 0.04) [31]. Okon et al. studied MVA in over 100 RCC
primary tumors in a quantitative fashion and found that
MVA was higher in ccRCC [32].To date no studies have
assessed the differences in MVA in corresponding primary
and metastatic specimens or in different histologic RCC
subtypes in a quantitative fashion.
Given the potential association between the degree of
tumor vascularity and response to VEGF or VEGR receptor
targeting therapy, our primary purpose was to determine
whether differences exist in MVA in matched primary and
metastatic sites, particularly given that many patients have
available archival specimens from either primary or the
metastatic tumors, but not both. Furthermore, seeing that
anti-angiogenic drugs are now used in non-clear cell RCC
patients, we sought to determine whether there are diffe-
rences in vessel density between the different histological
subtypes of RCC, which may be a predictor for response.
To analyze the microvessel area of tumor samples, we
utilized our system of automated quantitative analysis
(AQUA) which allows us to obtain more accurate objective
measures of compartment (vessel) area within tissues
[3,31,33]. Because of its ability to objectively assess
biomarkers on a continuous scale, AQUA has been shown
to outperform traditional "brown-stain" immunochemistry
in several studies [33-35].
Patients and methods
Patient cohorts and tissue microarray (TMA) construction
Two non-overlapping cohorts were used for these studies:
A cohort of matched primary and metastatic RCC cases
and a cohort of sequential nephrectomy cases with stage
I-IV disease. All tumor tissues were collected from the
Yale University Department of Pathology Archives. Speci-
mens and clinical information were collected with the
approval of a Yale University institutional review board.
Performance status, LDH, hemoglobin and calcium levels
were not available. TMAs were constructed using
standard methods with cores measuring 0.6 mm each.
Matched primary and metastatic RCC TMA
Thirty-four patients who had undergone both nephrectomy
and metastatectomy between 1978 and 2011 were identified
Histological subtypes included clear cell (91.2%) and mixed
histology (two cases, 8.8%). One mixed histology case was a
Figure 1 High (panel A) and low (panel B) microvessel area
(MVA) in matched primary and metastatic specimens by AQUA.
We used a cocktail of anti-cytokeratin and anti-carbonic anhydrase-9
conjugated to Cy2 to create a tumor mask (green), and anti-CD-34
conjugated to Cy5 (red) to identify microvessels. An example of a
patient with high MVAs in both the primary and metastatic
specimens is shown in panel A, and an example of low MVAs in
both primary and metastatic specimens is shown in panel B. The
corresponding MVA scores were 14.92% and 18.93%, respectively for
panel A and 4.26% and 6.78%, respectively for the patient
represented in panel B.
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type 2 papillary RCC. The other was a mixture of type 2
papillary RCC and unclassified RCC with oncocytic,
mucinous, and spindle cell features. Three percent
were of Fuhrman grade I and IV, 38% grade II and 56%
grade III. Age at diagnosis was 17–72 years (median-57).
The time between nephrectomy and metastatatectomy
ranged from 6 to 156 months, median 24 ± 39.5 months.
Only two patients were treated with VEGF or VEGF-R
targeting therapies. Metastatic sites included lung (13),
bone (7), soft tissue, skin and lymph node (8), adrenal
glands (2), liver (2), colon (1), and pituitary gland (1). Each
tumor site was represented by four cores from different
areas of the specimen; two cores from each tumor site
were included in each of two TMA blocks.
Large cohort RCC nephrectomy TMA
Specimens were collected from 334 non-overlapping
RCC patients who underwent nephrectomy between
1987 and 1999. This cohort has been described previously
[31,36]. Histological subtypes included clear cell (74%),
papillary (14%), mixed histology (4%), chromophobe (2%),
and oncocytomas (6%). The mixed histology subset
included clear cell with oncocytic features (2%) or with
papillary features (2%). Age at diagnosis was 25–87 years
(median-63). Among these patients, 56% had stage I
disease, 8% had stage II and III each, and 28% had stage
IV. Twelve percent were Fuhrman grade I, 52% grade II,
27% grade III and 9% grade IV. Tumors were represented
by two cores placed in two TMA blocks.
Immunofluorescent staining
Each slide was stained individually for CD-34, as previously
described with a mouse monoclonal anti-human CD-34
antibody incubated overnight at a dilution of 1:100 [3,31].
CD-34 was used as a vessel (endothelial cell) marker based
on studies by Yilmazer et al. which showed CD-34 immu-
nohistochemical staining to be more specific and sensitive
than CD-31 in determining microvessel density [37].
Automated image acquisition and analysis (AQUA)
Images were acquired and analyzed using algorithms that
have been previously described [33]. Monochromatic, high-
resolution (1024 × 1024 pixel, 0.5 μm) images were
obtained of each histospot using the 10X objective of an
Olympus BX-51 epifluorescence microscope with an auto-
mated microscope stage and digital image acquisition
driven by custom program and macro-based interfaces with
IPLabs sofware (Scanalytics). Coalescence of Cytokeratin/
CA-9/Streptavidin was used to localize the tumor compart-
ment. Endothelial cells were distinguished from tumor cells
by CD-34 expression. The percentage of CD-34 area within
the tumor area was used to determine the MVA. Histospots
were excluded if the tumor mask represented <3% of thehistospot area or if there was anomalous staining (lacking
DAPI or necrotic tissue).Statistical analysis
Statview and JMP 5.0 software were used (SAS Institute,
Cary, NC). MVAs for replicate tumor cores were averaged.
Associations between continuous MVA values and
pathological parameters were assessed using ANOVA.
Correlations between redundant histospots were assessed
by Pearson linear regression.Results
Measurement of microvessel area (MVA) by quantitative
immunofluorescence analysis in RCC
Given the role of angiogenesis in RCC, the area of CD-34
expressing cells within the tumor mask was measured in
both the primary and metastatic tumors of 34 patients.
Examples of high and low MVA in corresponding primary
and metastatic specimens are shown in Figure 1. MVA
distribution ranged from 0.44% to 25.19%, with a median
MVA of 4.95% in these specimens.
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To assess intra-tumor heterogeneity in vessel density, we
used four cores from the primary tumor and four cores
from the metastatic tumors, placed on two separate sets of
slides, each containing two cores from each site. MVAs
from corresponding cores of each array were averaged to
obtain a single concatenated value. The correlation between
the values from each array was calculated using the Pearson
test. Although some variability was seen, we found that the
averaged values from the two arrays were highly correlated,
R = 0.75 (P < 0.0001), as shown in Figure 2, indicating that
the intra-tumor consistency in MVA is high.Figure 3 Comparison between MVA in matching primary and
metastatic samples. Using paired t-tests, we compared MVA in 34
matched primary and metastatic specimens. As shown in the means
plot, while the primary specimens were slightly more vascular, the
difference was not statistically significant (P = 0.1).Comparison between MVA in matched primary and
metastatic specimens
Using analysis of variance (ANOVA), we found that
although the MVAs were minimally higher the pri-
mary specimens than their metastatic counterparts,
there was no statistically significant difference (P = 0.1),
as shown in the means plot in Figure 3. The mean MVA
was 7.86% in primary tumors and 5.62% in metastatic
tumors. To determine whether MVA in primary speci-
mens can be used as a proxy to determine MVA in meta-
static samples and vice-versa, we studied the correlation
between MVA in matched primary and metastatic speci-
mens using the Pearson correlation test. As shown in
Figure 4, there is a moderate linear association between
MVA in the two specimen types (R = 0.36), a number of
cases had discordance between the primary and metastatic
specimens.Figure 2 Correlations between microvessel area (MVA) in
different areas of a given tumor. Two tissue microarrays, each
containing duplicate histoscores taken from separate areas within
the matched primary and metastatic RCCs, were constructed. Vessel
Area, expressed as the percent area covered by CD-34 staining
within the tumor, demonstrates good array-to-array correlation, and
low intra-tumor variability, R = 0.75.MVA in the different histologic subtypes
Given that we only had 34 matched primary and metastatic
tumors, we employed a larger historical cohort of primary
nephrectomy RCC specimens to assess difference in MVA.
This cohort includes clear cell, papillary, chromophobe,
oncocytoma, and mixed histologies. MVA score distribu-
tion ranged from 0.1% to 25% (with a median value of
4.4%). The mean MVAs for the different subtypes were:
4.4% for clear cell, 1.28% for papillary, 1.98% for chromo-
phobe, 0.99% for mixed histology, and 2.5% for oncocyto-
mas. By ANOVA, we found that the clear cell subtype had
significantly higher MVA than papillary histology and
oncocytomas (P < 0.0001, and P = 0.018, respectively), as
shown in Figure 5. Individual p-values were generated
using the post-hoc Fisher PLSD (protected least significantFigure 4 Correlation between MVA in matched primary and
metastatic samples. Using the Pearson correlation test, we
assessed the association between MVA in the two tumor types;
while in some cases the association in strong, a fair degree of
discordance was seen.
Figure 5 Box plot demonstrating highest MVA in clear cell
histological subtype. MVA was studied in 334 primary RCC
specimens of different histologic subtypes. While the MVA was
variable in each subtype, clear cell carcinoma specimens had higher
MVAs than papillary histology and oncocytomas.
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cant differences were found between the other subtypes.
Discussion
In this work we studied MVA in two patient cohorts; one
cohort of matched primary and metastatic RCC specimens
and a larger cohort of over 300 primary nephrectomy spe-
cimens. We found that MVA, when measured in a quanti-
tative objective fashion, does not differ significantly in
different areas of the tumor. Paired comparisons between
the matched primary and metastatic sites revealed that the
primary specimens are slightly more vascular, but the
difference was not statistically significant. To determine
whether MVA in a primary specimen accurately reflects
that of corresponding metastases, we studied the corre-
lation between MVA in the two tumor types and found
that while there clearly is an association (R = 0.36), a fair
degree of discordance was seen. We note that the range of
time frames between nephrectomy and metastastatectomy
was wide, and sample size of matched primary and meta-
static specimens does not allow analysis of an association
between MVA and time to metastatic disease. Moreover,
our metastatectomy cohort might reflect patients with oli-
gometastases amenable to local therapy, rather than wide-
spread metastatic disease. Finally, using our larger cohort
of primary nephrectomy specimens, we found that the
clear cell carcinomas were significantly more vascular than
papillary histology. In our previous work we showed that
MVA is inversely correlated with Furhman grade, but
not with stage. Similarly, it was associated with improved
10-year disease-free survival [31].Although the first VEGF-R2 targeting drugs were
approved for metastatic RCC over seven years ago, no pre-
dictive assays have been validated for any of these drugs to
facilitate patient selection [8,9]. Vascular tumors should
respond to anti-angiogenic therapy, and the discordance in
responses of the primary and metastatic tissues is not well
explained by MVD. Recent data published by Zhao et al.
suggests that high MVD predicts better response to bevaci-
zumab in non small cell lung cancer [38]. Attempts to iden-
tify predictors of response based on imaging studies in
small groups of patients do suggest an association between
increased baseline tumor vascularity by DCE-MRI and
improved progression free survival (PFS) with sorafenib
[18]. Ueno et al. used PET/CT on 30 patients treated with
sunitinib or sorafenib and showed that baseline SUV uptake
correlated with short progression PFS, while decreased
SUV uptake after one month on therapy was a stronger
predictor of PFS [39]. Clinical factors (standard laboratory
values, performance status and time from diagnosis to
treatment) do appear to be associated with improved PFS
in patients treated with these drugs [40]. Models incorpor-
ating both clinical and radiographic criteria suggest that the
combined model is superior to either modality alone [41].
Whether or not these factors are predictive of benefit from
therapy as opposed to improved natural history of disease
remains to be determined.
While the abovementioned studies focused on radio-
graphic and clinical criteria, other early studies have
attempted to determine the association between pre-
treatment tumor-based characteristics and response to
VEGF or VEGF-R targeting drugs. For example, two
small retrospective cohort studies demonstrated an asso-
ciation between CAIX levels measured by immunohisto-
chemistry and response to VEGF-R2 targeting drugs
[42,43]. The purpose of the current study was to pave
the way for future studies of associations between MVA
and response to VEGF pathway targeted therapy. In pre-
vious studies we showed an inverse correlation between
MVA and VEGF-R1 and –R2, but no significant corre-
lation was found between MVA and VEGF [31]. Seeing
that no clear association has been demonstrated between
VEGF-R2 expression and response to VEGF-R targeted
therapy, incorporation of MVA in biomarker studies
may improve our ability to predict response. The major-
ity of patients in the present study were not treated with
these drugs, and the study was designed to determine
baseline MVA characteristics in primary and metastatic
RCC tumors. Seeing that most RCC patients in our
institution have larger archival specimens from either
the nephrectomy or the metastatectomy but not both
(as evident by the small size of the matched primary
and metastasis cohort relative to the nephrectomy cohort),
our finding of differences in some (but not all) patients in
MVA between primary and metastatic sites suggests that
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response should assess specimens from both sites. If
debulking nephrectomy is clinically indicated, MVA
should be assessed in the primary site, but otherwise may
be assessed at the metastatic site.
A number of clinical studies have reported discordance
in tumor shrinkage in primary and metastatic RCC tumors
in patients treated with VEGF pathway targeting drugs
treated with the primary tumor in situ. Abel et al. reported
that while tumor shrinkage was seen in primary sites, the
degree of shrinkage was smaller than in metastatic sites
[44]. Our study showed slightly higher MVA in primary
than metastatic sites, but this difference did not reach sta-
tistical significance. The smaller radiographic changes in
primary tumors than metastatic tumors is more likely due
to the mechanism of action of these drugs than differential
anti-tumor activity in primary and metastatic sites; the
anti-angiogenic effects likely cause necrosis in highly vas-
cular tumors which may not result in large changes in
tumor diameter. This hypothesis is supported by the
improved progression free survival with drugs such as
sorafenib in the setting of a low objective response
rate by standard radiographic criteria [10].
Another goal of this study was to assess intra-tumor
variability in MVA. We previously reported that in our
large cohort of primary tumors studying MVA using the
same automated method, intra-tumor variability was
negligible, and the MVA obtained from different parts of
the nephrectomy specimen was similar (ρ = 0.8) [31]. In
the present study we had similar findings; as shown in
Figure 2, using the smaller cohort of matched primary
and metastatic samples, we validate our previous obser-
vations. This suggests that MVA obtained from core bi-
opsies can reflect that of the entire tumor.
Historical concerns about bleeding from biopsies done
to diagnose RCC have largely been refuted in recent years.
The incidence of bleeding from biopsies from primary
renal specimens has been reported to be exceedingly low
in recent years, although most series did not evaluate
post-biopsy hemorrhage by imaging and did not assess the
incidence of bleeding from metastatic tumors [45,46].
While no clear association has been made between tumor
vascularity and hemorrhage, our data show that there
is no significant difference in vascularity between the
primary and metastatic sites, suggesting that tumor
vascularity should not be a consideration in deciding
anatomic preference for biopsy.
Clear cell RCC represents the most common histologic
subtype. Phase III studies of sunitinib, sorafenib, bevacizu-
mab, pazopanib and axitinib excluded non-clear cell histo-
logies [9-12,47]. Subsequent studies, however, showed that
these drugs may be beneficial in non-clear cell histologies
as well, although the efficacy in papillary RCC appears to
be lower than the historically reported response in clear cellRCC [48]. The response rate in the small number of
patients in this study with chromophobe RCC was
less disappointing. Here we show that vascularity of clear
cell RCC is higher than papillary and oncocytoma
subtypes, yet the MVA of chromophobe RCC was slightly
lower than that of clear cell RCC, but this difference did
not reach statistical significance (P = 0.063). The differences
in MVA demonstrated with this method may explain the
differences in response rate to anti-angiogenic therapies
with the different histological subtypes.
Conclusion
In summary, our data show that MVA within a tumor is
fairly uniform, suggesting that MVA measured from a
biopsy specimen is may represent that of the entire
tumor. Although MVA was slightly higher in primary
than metastatic specimens, this difference was not statis-
tically significant, suggesting that if MVA is associated
response to VEGF pathway targeting drugs, anti-tumor
effects should be seen in both primary and metastatic sites.
These studies need to be validated in additional, larger
cohorts. While there was a fair correlation between MVA
in matched primary and metastatic sites, discordant cases
were seen, indicating that future predictive biomarker
studies entailing MVA measurements should include
specimens from both sites to verify concordance in MVA
and further determine the association between MVA and
response to anti-angiogenic therapies. Clear cell carcinomas
have higher MVA than other histologic subtypes, which
may explain the higher response rate to VEGF pathway tar-
geting therapies in clear cell RCC. Further studies of MVA
using quantitative measurements such as those used here
should be incorporated into clinical trials of anti-angiogenic
drugs in RCC.
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